Kenneth Cohen

Kenneth Cohen is an independent adviser to entrepreneurs, companies, and investors, primarily in the life sciences, and an experienced corporate director and board chairman. Ken was previously Co-founder, President, and CEO of Somaxon Pharmaceuticals, a specialty pharmaceutical company. He was President and CEO of Synbiotics Corporation, a veterinary diagnostics company, and was Executive Vice President and COO for Canji, a gene-therapy company, until its acquisition by Schering- Plough in 1996. He served as Vice President of Business Affairs at Argus Pharmaceuticals and VP of Marketing & Business Development for LifeCell Corporation. Ken held numerous positions during 10 years at Eli Lilly, including Director of Business Planning for Medical Instrument Systems, which became Guidant, and managed the launch of Prozac®, one of the most successful drugs in history.

Ken received his A.B. degree from Dartmouth College and an M.B.A. from the Wharton School. In 1999, in recognition of his contributions to French-American business, the President of France named Ken a Chevalier of the National Order of Merit.

Mr. Cohen has been an advisor to and director of multiple pharmaceutical, medical device, and biotechnology companies. He is presently Chief Business Advisor to Pellficure Pharmaceuticals. Ken is Chairman Emeritus and a current member of the Board of

Trustees of the San Diego Humane Society, a leading charitable organization with more than 600 employees.

Mr. Cohen has been donating blood since 1974 and joined the Board in 2022.